Clinical Trials > PRONOVA RUBY RESEARCH REGISTRY (R3)

The study was conducted in Ruby Hall clinic, Pune. A total of 200 patients were enrolled and ProNOVA stents were deployed in these patients.

Methodology: The first 200 consecutive Pronova sirolimus eluting stents implanted at ruby hall from may 03 till sept 03 were followed up clinically for upto 6mths. No inclusion/Exclusion criterias were followed in the registry providing real life experience of ProNOVA. A total of 200 patients were enrolled and only 197 were followed as 3 patients were lost to followup.

Results

Study Demographics: The average age of patients was 55.84yrs of which 88% were males and 12% were females. A total of 237 stents were deployed in these patients. The vessel size was 2.5mm-3.5mm. The average number of stents deployed in patients was 1.21stents per patient.

Risk Profile: The risk profile of these patient population consisted of 33% diabetics, 36% hypertensives and 23% hyperlipidemics.

Vessel and Lesion Distribution:

Stent Details: Average stent length used in these patients was 21mm. Patients with 23mm or more stent length were 45% and patients with 28mm or more stent length were 24%. The number of patients with more than 1 stent was 26%.

Stent Length:

Stent Diameters:
Conclusions: It was found that a low MACE was observed at six months, thereby confirming the efficacy of the ProNOVA stent system. The efficacy of the ProNOVA stent system is also confirmed as the symptom driven TLR is highly encouraging.

Key Take Aways:

* 200 patients were enrolled hence a big study
* No inclusion and Exclusion criterias, hence results showing real world significance
* Low MACE was observed at 6 months thereby confirming efficacy of ProNOVA stent system